Buprenorphine formulations for the treatment of opioid use disorders a review of comparative clinical effectiveness, cost-effectiveness and guidelines
Currently, buprenorphine formulations for the treatment of opioid use disorder (OUD) include an implant, as well as oral formulations combined with an opioid antagonist, naloxone. This combination is designed to discourage abuse of buprenorphine, as naloxone can precipitate withdrawal symptoms in pa...
Main Authors: | , |
---|---|
Corporate Author: | |
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2017, July 31, 2017
|
Edition: | Version 1.0 |
Series: | CADTH rapid response report: summary with critical appraisal
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references